Insulin resistance, viral load and response to peginterferon and ribavirin in patients with chronic hepatitis C virus infection

Chia-Yen Dai, Jee-Fu Huang, Ming-Yen Hsieh, et al.

Gut 2010 59: 418
doi: 10.1136/gut.2009.199224
Insulin resistance, viral load and response to peginterferon and ribavirin in patients with chronic hepatitis C virus infection

We read the article by Moucari et al in *Gut* recently, with great interest. The authors concluded that insulin resistance (IR) is correlated independently with serum hepatitis C virus (HCV)-RNA and frequently encountered in patients with HCV genotype 4 (HCV-4) infection. Also IR is a major predictor of response to peginterferon and ribavirin in 108 HCV-4 patients receiving a 48-week course of peginterferon plus ribavirin.

In our previous study we enrolled 350 Taiwanese patients with chronic hepatitis C (CHC) (150 HCV genotype 1 (HCV-1) and 180 genotype non 1 (HCV-non 1)) to evaluate the association between homeostasis model assessment of IR (HOMA-IR) and response to therapy. We checked the association between HOMA-IR and serum HCV-RNA level. The mean serum HCV RNA levels were similar between high HOMA-IR (>2.5) and low IR (≤2.5) in all 330 patients with borderline statistical significance (4.97 ± 1.23 vs 5.05 ± 0.99 log IU/mL, p = 0.056). When using HOMA-IR 2 as a cut-off of high and low HOMA-IR as Moucari et al., we found the mean serum HCV RNA levels were similar between high HOMA-IR (>2) and low IR (≤2) in all 330 patients (5.26 ± 1.12 vs 5.18 ± 1.00 log IU/mL, p = 0.260) and in 150 HCV-1 patients (5.54 ± 0.94 vs 5.56 ± 1.00 log IU/mL, p = 0.464). The mean serum HCV RNA level was lower between high HOMA-IR (>2) and low IR (≤2) in 180 HCV-non-1 with borderline statistical significance (5.04 ± 1.20 vs 5.02 ± 0.98 log IU/mL, p = 0.067). Since Moucari et al. elucidated that the IR was correlated independently with serum HCV-RNA in HCV-4 patients, whether there is association between HOMA-IR and different HCV genotypes needs further studies.

Moucari et al. reported that IR is a major predictor of response to peginterferon and ribavirin in HCV-4 patients, which indeed meets with applause. We have found that HOMA-IR was associated with SVR to peginterferon plus ribavirin in HCV-1 patients, but not in HCV-non-1 patients. Romero-Gómez et al. and Conjeevaram et al. have also reported the high HOMA-IR impairs the response to combination therapy in HCV-1 patients in different countries and all the studies strengthen the important role of IR on the response to anti-HCV combination therapy in HCV-1 and -4 patients. By the way, the HCV viral load was an independent factor, in addition to HOMA-IR, associated with SVR in HCV-1²⁻⁴ patients. In HCV-4 patients Kamal et al. reported that the viral load was highly correlated with and the best predictive marker for peginterferon plus ribavirin responsiveness.³ It is noteworthy that Moucari et al. reported the HOMA-IR rather than the HCV RNA level is a predictor of viral response in HCV-4 patients which minimised the role of pretreatment HCV RNA level on the viral response when taking the HOMA-IR into consideration in HCV-4 patients.¹ We just wonder whether the association between the HOMA-IR and HCV RNA level still exists in these 108 HCV-4 patients? On the other hand, the impact of HOMA-IR on SVR rate was especially discovered among patients with HCV-1 infection and high serum HCV RNA level (defined as ‘difficult-to-treat’ patients) in our previous study. It seems interesting that whether this finding can also be depicted among the HCV-4 patients in the study of Moucari et al.

Chia-Yen Dai,¹,²,³ Jee-Fu Huang,¹,²,³,⁴ Ming-Yen Hsieh,¹ Wann-Long Chuang,¹,² Ming-Lung Yu¹

¹Hepatobiliary Division, Department of Internal Medicine, Kaohsiung Medical University Hospital, Kaohsiung, Taiwan; ²Faculty of Internal Medicine, College of Medicine, Kaohsiung Medical University, Kaohsiung, Taiwan; ³Department of Occupational and Environmental Medicine, Kaohsiung Medical University Hospital, Kaohsiung, Taiwan; ⁴Department of Internal Medicine, Kaohsiung Municipal Hsiao-Kang Hospital, Kaohsiung, Taiwan.

Coeliac disease: emerging in China?

We read with interest the leading article by Hunt and van Heel on recent advances in coeliac disease (CD) genetics.¹ They suggested that further investigation of the coeliac-associated single nucleotide polymorphisms (SNPs) in other populations was needed. Our recent work may help to push this research work in the Chinese population. Here we report on a serological screening for CD in China. CD has been historically considered to be absent in the Far East (China, Japan, Korea, Malaysia, etc.).² However, since the major known risk factors for CD are common in China, we used serological tests for immunoglobulin G (IgG) antigliadin antibodies (AAGs) and IgA antitissue transglutaminase antibodies (tTGs) to screen for CD in high risk patients,³ ⁴ comprising 75 cases of diarrhoea–predominant irritable bowel syndrome (IBS-D) and five cases of insulin-dependent diabetes mellitus (IDDm), 30 women and 48 men, mean age 50 ± 15 years old. Patients with IBS fulfilled symptom-based diagnostic Rome II criteria and in addition had loose stools with undegested food, frequent stools after eating

Competing interests None.

Provenance and peer review Not commissioned; not externally peer reviewed.

**REFERENCES**


